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Obesity has been often associated with the occurrence of cardiovascular diseases, type 2 diabetes, and cancer. The development of
obesity is also accompanied by significant differentiation of preadipocytes into adipocytes. In this study, we investigated the activity
of 𝛼-mangostin, a major xanthone component isolated from the stem bark of G. malaccensis, on glucose uptake and adipocyte
differentiation of 3T3-L1 cells focusing on PPAR𝛾, GLUT4, and leptin expressions. 𝛼-Mangostin was found to inhibit cytoplasmic
lipid accumulation and adipogenic differentiation. Cells treated with 50 𝜇Mof 𝛼-mangostin reduced intracellular fat accumulation
dose-dependently up to 44.4% relative to MDI-treated cells. Analyses of 2-deoxy-D-[3H] glucose uptake activity showed that 𝛼-
mangostin significantly improved the glucose uptake (𝑃 < 0.05) with highest activity found at 25𝜇M. In addition, 𝛼-mangostin
increased the amount of free fatty acids (FFA) released. The highest glycerol release level was observed at 50 𝜇M of 𝛼-mangostin.
qRT-PCR analysis showed reduced lipid accumulation via inhibition of PPAR𝛾 gene expression. Induction of glucose uptake and
free fatty acid release by 𝛼-mangostin were accompanied by increasing mRNA expression of GLUT4 and leptin. These evidences
propose that 𝛼-mangostin might be possible candidate for the effective management of obesity in future.
1. Introduction
The incidence of obesity has become a major public health
concern worldwide. Obesity is characterised by the accumu-
lation and deposition of excess fat in adipose tissues [1] and
increased deposition of cytoplasmic triglycerides [2], which
may lead to various metabolic and chronic diseases such as
cardiovascular diseases, type 2 diabetes, and cancer [3]. The
development of obesity in adults is also accompanied by sig-
nificant differentiation of preadipocytes into adipocytes [4].
In recent years, research studies on adipocytes have been
growing tremendously. Accordingly, adipocytes are emerging
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as a major drug target for diabetes and obesity-mediated
metabolic syndrome [5]. Adipose is not only known for its
capacity to store the excess of dietary energy in the form of
triglyceride [6], but has also been acknowledged to play an
important role in the control of energy metabolism [7, 8].
A number of transcription factors have been documented
to be involved in the adipogenesis, glucose uptake, and
glycolysis pathway [9]. These transcription factors include
peroxisome proliferator-activated receptor-𝛾 (PPAR𝛾), glu-
cose transporter-4 (GLUT4), and adipokines such as leptin.
PPAR𝛾 is predominantly expressed in adipose tissues
and plays a central role in adipose tissue functions [10].
PPAR𝛾 regulates the expression of genes associated with
insulin signalling and glucose and lipidmetabolism inmature
adipocytes [11]. Reduced expression of PPAR𝛾 has been
shown to be effective in inhibiting the adipogenesis of 3T3-
L1 cells [12]. GLUT4 is a high-affinity glucose transporter
predominantly expressed in insulin-sensitive tissues such as
muscle and adipocytes [13]. Increased expression and plasma
membrane translocation of GLUT4 have been found to lower
blood glucose and enhance glucose transport and utilisation
[14]. Leptin is produced mainly by adipocytes and found in
low levels in the gastric fundic epithelium, intestine, skeletal
muscle, mammary epithelium, placenta, and brain [15]. High
levels of circulating leptin in adipose tissues characterise
human obesity [16] and increased levels of body fat [17]. As a
result, the role of some gene expressions and the importance
of these expressions have been studied.
A detailed review of the literature shows that a few species
ofGarcinia have attracted the attention of health practitioners
[18]. For example, the fruit of G. cambogia has been shown
to have antiobesity effect [19, 20], affect the lipid metabolism
[21], and inhibit the cytoplasmic lipid accumulation as well
as adipogenic differentiation of preadipocytes [22].Moreover,
water-soluble calcium hydroxycitrate (HCA) as G. atroviridis
has been used for the treatment of obese women [23], while
G. indica (hydroxycitric acid) has been used as a weight
loss supplement for obese patients [24]. Due to the presence
of active compounds in different Garcinia species, Garcinia
has been regarded as an interesting choice to be studied
further.The species ofGarcinia have been reported to possess
a lot of bioactive molecules such as xanthones, flavonoids,
benzophenones, lactones, and phenolic acids [25]. Recently,
the stem bark of G. malaccensis has been shown to contain
xanthones, namely, 𝛼-mangostin as the major compound
[26]. Interestingly, the most studied xanthone of Garcinia
species is 𝛼-mangostin for which antibacterial [27], antiox-
idant [28], anti-inflammatory [29–31], antiproliferative [32],
proapoptotic [33–35], and anticarcinogenic [36–39] activities
have already been reported.
This paper reports the effect of 𝛼-mangostin isolated
from the stem bark of G. malaccensis on 3T3-L1 adipocytes
via the adipogenesis and glucose uptake activity. In this
study, we evaluated the effect of 𝛼-mangostin on the cell
viability based on the MTT assay and quantification of lipid
accumulation in 3T3-L1 cells. We also examined insulin-
induced glucose uptake into 3T3-L1 adipocytes as a measure
by the liquid scintillation counter. Finally, qRT-PCR analysis
was performed in order to find out the gene expression
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Figure 1: The purity of 𝛼-mangostin was determined using HPLC
analysis. (a) Chemical structure of 𝛼-mangostin. (b) The amount
was measured by HPLC technique. The peak of 𝛼-mangostin was
observed at retention time of 13.05min.
responsible for the 𝛼-mangostin ability to reduce lipid accu-
mulation in adipose tissues. As a result, we demonstrated
that 𝛼-mangostin may reduce lipid accumulation as well as
stimulate glucose uptake by the cells and may be a promising
candidate as an antiobesity agent.
2. Materials and Methods
2.1. Plant Materials and Isolation of 𝛼-Mangostin. 𝛼-
Mangostin was isolated from G. malaccensis [26]. The purity
of the isolated 𝛼-mangostin was approximately 94% as
identified by HPLC (Figure 1) and compared to the reference
standard of purity 96.5% of 𝛼-mangostin (C
24
H
26
O
6
) from
ChromaDex (Irvin, CA) [40]. Mouse 3T3-L1 fibroblast
(CL-173) was obtained from the American Type Culture
Collection (ATCC), Virginia, USA.
2.2. HPLC Analysis. Quantification of 𝛼-mangostin was per-
formed according to method described by Elsaid Ali et al.
[40]. The HPLC system (Shimadzu, Japan) consisted of a
quaternary pump (LC-20AT), autosampler (SIL-20A HT),
solvent degasser unit (DGU-20A 5R), diode array detec-
tor (SPD-M20A), and column oven (CTO-10AS VP). The
quantification wavelength of 𝛼-mangostin was set at 316 nm.
The chromatographic separation was performed at ambient
temperature (25–28∘C) using Hypersil BDS C
18
column (4.6
× 100mm, 3 𝜇m size) (Thermo Scientific, USA) with C
18
guard column. The mobile phase consisted of acetonitrile
(A) and 0.1% (v/v) orthophosphoric acid (H
3
PO
4
) diluted in
water (B) was delivered at flow rate of 1.0mL/min following
programmed gradient elution: 70% (A) isocratic for 6min,
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Table 1: Differentiation scheme of adipocytes.
Day Negative control Positive control Treatment group
0 No inducer (solvent 0.1% ethanol)
Dexamethasone (0.25 𝜇M)
IBMX (0.5mM)
Insulin (1.0𝜇g/mL)
Dexamethasone (0.25 𝜇M)
IBMX (0.5mM)
𝛼-Mangostin (10, 20, 50 𝜇M)
2 No inducer (solvent 0.1% ethanol) Insulin (100 nM) Insulin (100 nM)
4–8 Complete medium Complete medium Complete medium
70–75% (A) in 1.2min, 75–80% (A) in 0.4min, 80% (A)
isocratic for 2.4min, 80–70% (A) in 0.4min, and finally 70%
(A) isocratic for 5min as postrun for reconditioning. Sample
injection volume was adjusted to 10 𝜇L. Total running time
was 17min. All solutions of mobile phase were freshly pre-
pared, filtered through 0.45 𝜇m Nylon filter under vacuum,
anddegassed by sonication for 20min prior to use.The results
were analysed usingChemStation software.The percentage of
𝛼-mangostin in the extract was calculated based on the peak
area.
2.3. Cell Culture. 3T3-L1 preadipocytes were grown in Dul-
becco’sModified EagleMedia (DMEM) containing 10% foetal
bovine serum (FBS), 1% penicillin (10.000U/mL), and 1%
streptomycin (10.000𝜇g/mL supplemented in 37∘C incubator
in a humidified atmosphere of 5% CO
2
). Cells were subcul-
tured every 3 to 4 days at approximately 80% confluence.
2.4. Cell Viability. Cell viability was assessed by 3-(4,5-dim-
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Mature adipocytes were seeded in 96-well plates
and grown until confluence. 𝛼-Mangostin was dissolved in
dimethyl sulfoxide (DMSO) and treated for 48 h. Our pre-
liminary study showed that DMSO at a final concentration of
<0.1% in media did not affect cell viability or differentiation.
Cells were then washed two times with phosphate buffer
saline (PBS). 20 𝜇L of MTT stock solution (5mg/mL) was
added to each well and the plates were further incubated for
4 h at 37∘C. 100 𝜇L of DMSO was added to each well to solu-
bilise the water-insoluble purple formazan crystals [41]. After
1 h, the absorbency was measured at wavelength of 570 nm
and reference wavelength of 630 nmwith amicroplate reader.
2.5. Adipocyte Differentiation. Cells were seeded onto 12-
well plates at a density of 2 × 104 cells/well. Two days
after confluence (defined as day-0), cells were stimulated to
differentiate with differentiation medium containing DMEM
with 10%FBS andMDI [0.5mM3-isobutyl-1-methylxanthine
(IBMX), 0.25𝜇M dexamethasone, and 1 𝜇g/mL insulin] for
2 days. In the course of screening adipocyte differentiation-
inhibitory activity, 3T3-L1 preadipocytes were treated with
differentiation medium in the presence of various concentra-
tions of test compound (10, 25, and 50 𝜇M of 𝛼-mangostin)
at day-0. At day-2, differentiating medium was replaced
with 10% FBS/DMEM medium containing 1 𝜇g/mL insulin
and incubated for another two days (day-4). Thereafter,
the cells were maintained in 10% FBS/DMEM medium for
an additional 4 days (day-8) with medium changes every 2
days [42]. Adipocytes differentiation scheme was summa-
rized in Table 1.
2.6. Oil Red O Staining. Eight days after the differentiation
induction, cells were washed three times with PBS and fixed
with 10% formalin for 1 h at room temperature. After fixation,
cells were washed once with PBS and stained with freshly
diluted Oil Red O solution (3 parts of 0.6% Oil Red O in
isopropanol and 2 parts of water) for 1 h. Cells were then
washed twice with distilled water and visualised under a
microscope. Images were collected on an Olympus (Tokyo,
Japan) microscope. For quantitative analysis, Oil Red O
stain was dissolved with isopropanol and optical density was
measured at 520 nm by enzyme-linked immunosorbent assay
(ELISA) plate reader [43].
2.7. Deoxy-[3H]-D-glucose Uptake Assay. Glucose uptake
activity was analysed by measuring the uptake of radiola-
belled glucose from the culture medium by adipocytes [42].
Briefly, the differentiated adipocytes, whichwere grown in 12-
well plates, were washed twice with serum-free DMEM and
incubated for 3 h at 37∘C with 1mL of serum-free DMEM.
The cells were then washed three times with Krebs-Ringer
HEPES (KRPH) buffer (118mM NaCl, 5mM KCl, 1.3mM
CaCl
2
, 1.2mMMgSO
4
, 1.2mMKH
2
PO
4
, and 30mMHEPES,
pH 7.4) and incubated with 0.9mL of KRPH buffer for
30min at 37∘C. 𝛼-Mangostin (10, 25, and 50 𝜇M) including
the control was added, and the cells were incubated at
37∘C for further 60min. Glucose uptake was initiated by
the addition of 0.1mL of KRPH buffer containing 2-deoxy-
D-[3H]-glucose (0.037MBq; Perkin Elmer Inc., USA) and
glucose (0.001mM).After 60min, the cells werewashed three
times with ice-cold PBSA to stop the glucose uptake. The
cells were then lysed through incubation for 20min at 37∘C
with 0.7mL of 1% Triton X-100.The radioactivity levels in the
cell lysates were determined using a Tri-Carb 2700TR liquid
scintillation counter, Packard InstrumentCo. (USA). Samples
from each lysate were counted and measured in triplicate.
2.8. Adipolysis Assay. Adipolysis assay kits (Cayman Chem-
ical, USA) was used to study the adipolysis of triglycerides
in differentiated 3T3-L1 cells. In order to perform the assay,
the culturemediumwas carefully aspirated and replaced with
fresh medium containing the various concentrations of 𝛼-
mangostin (10, 20, and 50 𝜇M). The isoproterenol solution
was used as a positive control. Test compound (𝛼-mangostin)
and positive control were used to induce adipolysis and
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Figure 2: Stained fat droplets after differentiation programme (magnification 200x). (a) Insulin. (b) DMSO (negative control). (c) MDI-
treated cells. ((d)–(f)) 𝛼-Mangostin, 10, 25, and 50𝜇M, respectively.
the amount of detectable free glycerol depend on the activity
of the samples. Absorbance was finally measured at 540 nm.
2.9. Quantitative Reverse Transcriptase Polymerase Chain Re-
action (qRT-PCR) Analysis. Total RNA was extracted using
Trizol reagent (Invitrogen, USA). The mRNA in the samples
was reverse-transcribed into cDNAusingQuantiTect Reverse
Transcription (Qiagen) kit according to the manufacturer’s
instructions.The resulting cDNAwas amplified by PCRusing
the following primer pairs: mouse PPAR𝛾 (sense 5-TTT-
TCAAGGGTGCCAGTTTC-3 and antisense 5-AATCCT-
TGGCCCTCTGAGAT-3), GLUT4 (sense 5-CAGCTCTCA-
GGCATCAAT-3 and antisense 5-TCTACTAAGAGCACC-
GAG-3), and leptin (sense 5-GGAGGAATCCCTGCTCCA-
GC-3 and antisense 5-CTTCTCCTGAGGATACCTGG-3).
The housekeeping beta-actin gene was amplified using the
sense primer 5-ACACCCCAGCCATGTACG-3 and the anti-
sense primer 5-TGGTGGTGAAGCTGTAGCC-3.
2.10. Statistical Analysis. Data are presented as means ±
standard error of three experiments. Data were analysed by
ANOVA using SPPS version 19. A 𝑃-value of less than 0.05
was considered statistically significant.
3. Results and Discussion
3.1. Effect of 𝛼-Mangostin on the Viability of 3T3-L1 Cells. The
viability assay was used to determine any possible adverse
effects of 𝛼-mangostin (isolated from G. malaccensis) on the
cells.The concentrations of 0, 10, 20, and 50𝜇Mhad no effect
on the cell viability. Based on the MTT assay, the dosage of
100 𝜇M significantly (𝑃 < 0.05) decreased the cell viability
and therefore was not used as treatment dose in this study.
3.2. Reduction of Intracellular Lipid Accumulation in
3T3-L1 Cells by 𝛼-Mangostin. Eight days after treatment,
preadipocytes differentiation was terminated and stained
with Oil Red O. Fat droplets in these cells were visualised
and photographed (Figure 2). Quantification of lipid
accumulation by using UV spectrophotometer at 520 nm
showed that cells treated with 𝛼-mangostin reduced
intracellular fat accumulation dose-dependently up to
44.4% relative to MDI-treated control cells at the dose
of 50𝜇M (Figure 3). Therefore, our results demonstrated
that 𝛼-mangostin added to the adipocyte inducer (IBMX,
dexamethasone, and insulin) showed antiadipogenic activity
as evidenced by decreased triglyceride accumulation
in 3T3-L1 cells at all of the tested concentrations. This
unique mechanism of decreased lipid formation [19] by
𝛼-mangostin further prompted us to study the characteristic
effect of 𝛼-mangostin on adipocyte differentiation by using
the quantitative RT-PCR. Since most studies have shown
that PPAR𝛾 is one of the target genes in the induction
of adipocyte differentiation [11], owing to the same fact,
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Figure 3: Effect of different concentration of 𝛼-mangostin (10,
25, 50 𝜇M) on the differentiation of 3T3-L1 adipocytes. Data is
represented as mean ± SD, with 𝑛 = 3 per group. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01 compared to MDI-treated cells.
the same gene was used to determine the mechanism for the
inhibitory effect of 𝛼-mangostin on the 3T3-L1 cells.
3.3. Stimulation of Glucose Uptake in Mature 3T3-L1
Adipocytes by 𝛼-Mangostin. As PPAR𝛾 ligands can affect
the adipocyte differentiation and are reported to have an
effect on glucose uptake in 3T3-L1 adipocytes [44], hence,
the next part of this study was designed to evaluate the effect
of 𝛼-mangostin on the glucose uptake and insulin sensitivity.
To determine 2-deoxy-D-glucose (2-DG) uptake stimulation
by 3T3-L1 adipocytes, mature 3T3-L1 adipocytes were treated
with 𝛼-mangostin at the indicated concentrations (10, 25,
and 50 𝜇M) for 60min, and then glucose uptake activity
was assessed. The cells were treated with metformin (1mM)
and sodium orthovanadate (5mM) as positive controls,
and undifferentiated DMSO treated cells were used as a
negative control for the assay. The results indicated that
the 𝛼-mangostin stimulated the glucose uptake in 3T3-L1
adipocytes. However, the insulin-induced glucose uptake
was decreased by 𝛼-mangostin at 50𝜇M. This finding was
interesting since the test compound also reduced lipid
formation at the same dose for up to 44.4% compared to
the MDI-treated cells. This raised our attention to further
evaluate the mechanism of related mRNA expression.
Figure 4 illustrates the insulin-stimulated glucose uptake
by the compounds. Levels of radioactivity in the cell lysates
were determined using a liquid scintillation counter.
Adipocyte formation (adipogenesis), which occurs in
several stages, is the development of mature fat cells from
preadipocytes. This process includes alteration of cell shape,
growth arrest, clonal expansion, and a complex sequence of
changes in gene expression and storage of lipid [45]. Based
on the above findings, it appears that our findings related
to the effect of 𝛼-mangostin on 3T3-L1 adipocytes were in
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Figure 4: The effects of different concentration of 𝛼-mangostin
(10, 25, 50 𝜇M) in glucose uptake of 3T3-L1 adipocytes. Data is
represented as mean ± SD, with 𝑛 = 3 per group. ∗𝑃 < 0.05
compared to control group (DMSO treated cells), a = significant at
indicated concentration.
agreement with several other reports [46, 47] stating that
compound that inhibits adipocyte differentiation can also
improve glucose uptake in the 3T3-L1 adipocytes.
In adipocytes, basal (cells treated with normal glucose
without the presence of insulin and 2-deoxy-D-[3H]-glucose)
and insulin-stimulated glucose uptake activity require a
glucose transporter. Insulin can accelerate glucose entry
by affecting the translocation of GLUT4 from intracellular
stores to the plasma membrane [48]. In general, it is known
that GLUT4 provides insulin-stimulated glucose transport
in adipocytes [49]. Moreover, GLUT4 is expressed only in
adipocytes and its expression is regulated by PPAR𝛾 [50].
Therefore, to go for any conclusion in this study, it seemed
crucial to evaluate the expression of these genes in order to
understand the mechanism of glucose uptake in the 3T3-L1
adipocytes.
3.4. Induction of Adipolysis by 𝛼-Mangostin. Figure 5 shows
that the adipolysis assay served as confirmatory results for
the adipogenesis assay. The amount of glycerol released into
the medium was proportional to the level of triglyceride
storage and degree of adipolysis. It was found that cells
treated with 𝛼-mangostin increased the amount of free fatty
acid released into the medium. It was further observed that
the 𝛼-mangostin result was similar with the isoproterenol
(10 𝜇M), which was used as the positive control for the study.
Lipolysis was measured by quantifying the glycerol released
into the medium. Lipolysis in adipocytes is modulated in
a stepwise fashion by several genes including the leptin.
After this gene initiates the lipolysis pathway by releasing the
fatty acids, glycerols are also released [51]. Moreover, it has
been reported that plant extracts that inhibit the adipocyte
differentiation of 3T3-L1 cells will also decrease the serum
triglyceride levels in the adipose tissue [52]. These evidences
6 Evidence-Based Complementary and Alternative Medicine
0.1
0
0.2
0.3
0.4
0.5
0.6
0.7
Is
op
ro
te
re
no
l
(1
0
𝜇
M
)
Ab
so
rb
an
ce
 (5
4
0
nm
)
10𝜇M
25𝜇M
50𝜇M
∗
∗
∗
∗
C
on
tro
l
(D
M
SO
)
𝛼
-M
an
go
sti
n
Figure 5: Glycerol release of different concentration of 𝛼-mangostin
(10, 25, 50 𝜇M) from the 3T3-L1 cells. Data is represented as mean ±
SD, with 𝑛 = 3 per group. ∗𝑃 < 0.05 compared to control group
(DMSO treated cells).
show that decreased adipocytes differentiation may trigger
the adipocytes to release the triglyceride into the medium.
Generally, triglyceride can be converted into glycerol and
free fatty acid when released into the medium. The data
from the study showed that 𝛼-mangostin enhanced lipolysis,
and the efficacy of this action improved proportionally with
the increase in concentration of 𝛼-mangostin. The highest
glycerol release level was observed for cells treated with 𝛼-
mangostin at 50𝜇M.
3.5. Inhibition of 3T3-L1 Adipocyte Differentiation Involving
PPAR𝛾. To further assess the activity of 𝛼-mangostin on
PPAR𝛾 mRNA expression, 3T3-L1 preadipocytes were cul-
tured with the indicated concentration of the compound
(25 𝜇M) in the presence of MDI. This method can evaluate
the stimulation or inhibitory effect of the test compound
on adipocyte differentiation. As shown in Figure 6, cells
treated with 𝛼-mangostin showed reduced activity of PPAR𝛾
level when compared with the basal. Insulin (100 nM) was
used as the positive control [53]. Increased expression of
PPAR𝛾 induces adipocyte differentiation in 3T3-L1 cells
whereas the suppression of PPAR𝛾 expression blocks the lipid
formation [12]. In this study, analysis of the gene expression
demonstrated that the 3T3-L1 cells treated with 𝛼-mangostin
significantly downregulated the PPAR𝛾 expression. There-
fore, we can deduce that the reduction in PPAR𝛾 may be the
key step in the inhibition of adipocyte differentiation [22] in
3T3-L1 and that the targeting of PPAR𝛾 could be the main
mechanism for blocking of adipocyte differentiation by the
𝛼-mangostin.
3.6. Upregulation of Transcription of GLUT4 in 3T3-L1 Cells
by 𝛼-Mangostin. Afterward, we investigated the effects of 𝛼-
mangostin on the GLUT4 mRNA expression. As mentioned
previously, the glucose uptake activity in adipocytes is related
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Figure 6: Effects of 𝛼-mangostin (25 𝜇M) on PPARymRNA expres-
sion. Data is represented as mean ± SD, with 𝑛 = 3 per group.
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Figure 7: Effects of 𝛼-mangostin (25 𝜇M) on GLUT4 mRNA
expression. Data is represented as mean ± SD, with 𝑛 = 3 per group.
∗
𝑃 < 0.05 compared to control group (DMSO treated cells).
to the expression of glucose transporters. In this study, it
was observed that all the GLUT4 mRNA expression in fully
differentiated adipocytes increased significantly after treat-
ment with 𝛼-mangostin (Figure 7). This result demonstrated
that the 𝛼-mangostin promoted glucose uptake in 3T3-L1
adipocytes via the upregulation of GLUT4 expression.
GLUT4, which transports glucose from blood into tissue,
is the principal glucose transporter among several isotypes
of glucose transporters in insulin-sensitive tissues such as
skeletal muscle and adipocytes [47]. Decrease in the translo-
cation of GLUT4 to the plasma membrane has been found
to be the major cause of insulin resistance [46], and it is
required to activate GLUT4 in skeletal muscle to improve
insulin resistance and tomaintain blood glucose homeostasis.
Metformin, which is one of the widely used antidiabetic
drugs, can enhance the insulin-stimulated glucose uptake by
increasing the cell surface GLUT4 content [11]. In this study,
to assess whether the increased glucose uptake stimulated
by 𝛼-mangostin was due to the translocation of GLUT4,
the amount of GLUT4 expression present in the cells was
measured by using the quantitative qRT-PCR.
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Figure 8: Effects of 𝛼-mangostin (25 𝜇M) on leptin mRNA expres-
sion. Data is represented as mean ± SD, with 𝑛 = 3 per group.
∗
𝑃 < 0.05 compared to control group (DMSO treated cells).
As shown previously, the 𝛼-mangostin treatment signif-
icantly (𝑃 < 0.05) upregulated the mRNA expression of
GLUT4 gene in fully differentiated adipocytes. This result
indicates that the 𝛼-mangostin accelerated basal and insulin-
mediated glucose uptake by upregulating the GLUT4 expres-
sion. Decreased GLUT4 expression in adipose tissue is
associated with obesity and type 2 diabetes in humans [54].
Thus, it is important to use a compound that could improve
glucose uptake and stimulate GLUT4 expression.
3.7. Role of 𝛼-Mangostin in Leptin Expression. Finally, in
the gene expression analysis, we evaluated the effect of 𝛼-
mangostin on leptin expression to signify the free fatty acid
release from the cells into the medium. Analysis with 𝛼-
mangostin (25𝜇M) showed that the compound increased
the leptin expression and the result was similar with insulin
(100 nM) that was used as the positive control for the study
(Figure 8). This result suggests that 𝛼-mangostin treatment
may release the free fatty acid into the medium, which was
confirmed by the leptinmRNA expression. In obese individ-
uals, plasma leptin and free fatty acid are both elevated. Since
free fatty acid also reduces plasma leptin levels in the in vitro
study [5], it has been speculated that obesity may be caused
by the abnormality in the leptin-reduction mechanism of
free fatty acids. Alternatively, leptin resistance, which has
been considered to be present in obesity, might overcome the
decrease in leptin induced by free fatty acid [55].
4. Conclusion
In summary, the present study has shown that 𝛼-mangostin
isolated from G. malaccensis reduces lipid accumulation
with decreased PPAR𝛾 expression as well as stimulating the
glucose uptake and free fatty acid release from the cells via
GLUT4 and leptin expression. Taken together, these results
indicate that 𝛼-mangostin derived from G. malaccensis may
be a candidate for preventing metabolic disorders such as
obesity particularly among diabetics.
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